MapLight Therapeutics
MPLT
106 hedge funds and large institutions have $941M invested in MapLight Therapeutics in 2026 Q2 according to their latest regulatory filings, with 37 funds opening new positions, 22 increasing their positions, 29 reducing their positions, and 10 closing their positions.
270% more first-time investments, than exits
New positions opened: 37 | Existing positions closed: 10
87% more capital invested
Capital invested by funds: $502M → $941M (+$439M)
31% more funds holding
Funds holding: 81 → 106 (+25)
3.4% more ownership
Funds ownership: 58.21% → 61.61% (+3.4%)
11% less funds holding in top 10
Funds holding in top 10: 9 → 8 (-1)
24% less repeat investments, than reductions
Existing positions increased: 22 | Existing positions reduced: 29
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $907K
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
T. Rowe Price Associates
Baltimore,
Maryland
|
+$37.7M |
| 2 |
PBA
Paradigm Biocapital Advisors
New York
|
+$19.7M |
| 3 |
Fidelity Investments
Boston,
Massachusetts
|
+$17.8M |
| 4 |
State Street
Boston,
Massachusetts
|
+$14.8M |
| 5 |
Capital World Investors
Los Angeles,
California
|
+$12M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
ACM
ADAR1 Capital Management
Austin,
Texas
|
-$10M |
| 2 |
BlackRock
New York
|
-$9.05M |
| 3 |
VPC
Vestal Point Capital
New York
|
-$8.54M |
| 4 |
BOCH
Blue Owl Capital Holdings
New York
|
-$7.94M |
| 5 |
RCM
RA Capital Management
Boston,
Massachusetts
|
-$5.05M |
MPLT Hedge Fund Activity: Q2 2026 in Review
106 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in MapLight Therapeutics (MPLT) for Q2 2026, worth a combined $941M — up 87% from $502M a quarter earlier.
Buyers outnumbered sellers: 37 funds opened new MPLT positions and 10 closed out — a net gain of 27 holders — while 22 added to existing stakes and 29 trimmed.
The largest buyer was T. Rowe Price Associates, adding an estimated $37.7M. The largest seller was ADAR1 Capital Management, cutting an estimated $10M.
- 106 institutional investors held MapLight Therapeutics (MPLT) as of Q2 2026, up from 81 in Q1 2026.
- Funds reported $941M of MapLight Therapeutics stock for Q2 2026, up 87% quarter-over-quarter.
- 37 funds opened new MapLight Therapeutics positions in Q2 2026 and 10 closed out, a net change of +27 holders.
- The largest MapLight Therapeutics buyer in Q2 2026 was T. Rowe Price Associates, an estimated $37.7M added.
- The largest MapLight Therapeutics seller in Q2 2026 was ADAR1 Capital Management, an estimated $10M sold.
Based on aggregated 13F filings for Q2 2026.